Depo-Provera® and bone density

Journal of Family Planning and Reproductive Health

Volumn 28, Issue 1, 2002, Pages

  Gbolade, Babatunde A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; FOLLITROPIN; LEVONORGESTREL; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; CONTRACEPTIVE AGENT;

AMENORRHEA; BONE DENSITY; CLINICAL RESEARCH; DRUG MECHANISM; DRUG SAFETY; ESTRADIOL BLOOD LEVEL; HORMONAL CONTRACEPTION; HUMAN; ORAL CONTRACEPTION; OSTEOPENIA; OSTEOPOROSIS; OVULATION INHIBITION; REVIEW; RISK ASSESSMENT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; INJECTION; MEDICAL EDUCATION; RISK FACTOR;

BONE DENSITY; CONTRACEPTIVE AGENTS, FEMALE; EDUCATION, MEDICAL, CONTINUING; FEMALE; HUMANS; INJECTIONS; MEDROXYPROGESTERONE 17-ACETATE; OSTEOPOROSIS; RISK FACTORS;

EID: 0036170883     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118902101195910     Document Type: Review

References (51)

1. Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception
2. Oestrogenic activity in women receiving an injectable progestogen for contraception
3. A cross-sectional study of plasma FSH and LH levels in women using sequential, combination or injectable steroid contraceptives over long periods of time
4. Plasma levels of oestrogens during long-term treatment with depo-medroxyprogesterone acetate as a contraceptive agent
5. Bone density in long term users of medroxyprogesterone acetate
6. A prospective study on the effects of depot medroxyprogesterone acetate on trabecular and cortical bone after attainment of peak bone mass
7. Development of mass, density, and estimated mechanical characteristics of bones in Caucasian females
8. Skeletal development and bone turnover revisited
9. Attainment of peak bone mass
10. Bone mineral mass consolidation in young British adults
11. Spinal bone loss and ovulatory disturbances
12. Bone mineralization, hypothalamic amenorrhoea, and sex steroid therapy in female adolescents and young adults
13. Bone loss, contraception and lactation
14. Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis
15. Epidemiology of osteoporosis and osteoporotic fractures
16. Consensus statement: Osteoporosis, classification and clinical features
17. Osteoporosis - An update
18. The predictive value of bone loss for fragility fractures in women: A longitudinal study over 15 years
19. Age and bone mass as predictors of fracture in a prospective study
20. Prediction of postmenopausal fracture risk with use of bone mineral measurements
21. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group
22. Bone densitometry of the radius, spine and proximal femur in osteoporosis
23. Long-term fracture prediction by bone mineral assessed at different sites
24. Performance evaluation of a dualenergy X-ray bone densitometer
25. Bone density in women receiving depot medroxyprogesterone acetate for contraception
26. Spinal bone density in women using depot medroxyprogesterone for contraception
27. Recovery of bone density in women who stop using medroxyprogesterone acetate
28. Short-term effects of high dose oral medroxyprogesterone acetate on bone density in premenopausal women
29. Forearm bone density in users of Depo-Provera® as a contraceptive method
30. Bone density among long-term users of medroxyprogesterone acetate as a contraceptive
31. Long-term depot-medroxyprogesterone acetate and bone mineral density
32. Further evaluation on long-term depot-medroxyprogesterone acetate use and bone mineral density: A longitudinal cohort study
33. Steroid hormone contraception and bone mineral density: A cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health
34. Trabecular bone in long-term depotmedroxyprogesterone acetate users
35. Cortical and trabecular bone status in elderly women with femoral neck fracture
36. Changes in the trabecular pattern of the upper end of the femur as an index of osteoporosis
37. Bone mineral density in long-term depot medroxyprogesterone acetate acceptors
38. The distribution of cortical and trabecular bone mass along the lengths of the radius and ulnar and the implications for in vivo bone mass measurements
39. Bone mineral density during long-term treatment with Norplant® implants and depot medroxyprogesterone acetate: A cross-sectional study of Thai women
40. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women
41. Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis: Inference from a cross-sectional model
42. Bone mineral density in women using depot medroxyprogesterone acetate for contraception
43. A prospective comparison of bone density in adolescent girls receiving depot-medroxyprogesterone acetate (Depo-Provera®), levonorgestrel (Norplant®), or oral contraceptives
44. Does depot-medroxyprogesterone acetate reduce bone mineral density in adolescent users? Results of a pilot study
45. Bone mineral changes during pregnancy and lactation: A longitudinal cohort study
46. Bone mineral loss during lactation and recovery after weaning
47. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal postmenopausal women